30 closest matches · ranked by relevance
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Brain Neoplasms
Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months
Glioblastoma
Primary: Overall Survival (OS) Time — 26.3; 26.3 Months — p=0.8623
Brain Cancer
Primary: Overall Survival (OS) — 13.40; 14.88 Months — p=0.0037
Glioblastoma
Primary: Overall Survival (OS) Time — 16.3; 14.5; 13.4 Months — p=0.0328
Glioblastoma Multiforme
Primary: Progression Free Survival PPX/RT Versus TMZ/RT for Patients With GBM Without Methylation — 31; 15 participants
Gliosarcoma · MGMT-Unmethylated Glioblastoma
Primary: Progression-free Survival (PFS) (Phase II) — 8.5; 7.7 months — p=0.96
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Colorectal Cancer
Primary: Overall Response Rate — 0; 0; 5; 4 Participants
Glioblastoma
Primary: Progression Free Survival at 6 Month — 61.3; 55.7 percentage of patients
Glioma
Primary: MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery — 333.7; 105.1 fmol/mg of proteins — p=0.09
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Glioblastoma Multiforme
Primary: Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months — 79.31; 42.59 percentage of participants — p=<0.0001
Glioblastoma, Adult
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 2 Participants
Newly Diagnosed Glioblastoma
Primary: Overall Survival (OS) — 16.13; 15.08 Months
Malignant Glioma · Recurrent Glioblastoma
Primary: T-cell (Immunologic) Changes in Blood
Glioblastoma · Astrocytoma, Grade IV · Giant Cell Glioblastoma
Primary: Median Overall Survival — 16; 20; 19 months — p=0.072
Glioblastoma
Primary: Number of Patients With Investigator Defined Dose Limiting Toxicities (DLT) During the RT Phase — 1; 0; 2; 0 Participants
Leukemia, Acute Myeloid · Myelodysplastic Syndrome
Primary: Clinical Response at the End of Temozolomide Induction — 10; 2; 4; 8 participants
Glioblastoma · Gliosarcoma
Primary: Overall Survival (OS) — 18.7; 18.9 months — p=0.633
Glioma
Primary: Number of Participants With DLT- Phase I — 2; 0; 4 participants
Glioblastoma Multiforme
Primary: Progression-free Survival (PFS) — 11.3 Months
Brain Cancer
Primary: Time to Cognitive Failure — 7.7; 4.9 months — p=.74
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Maximum Tolerated Dose of MGd (Phase I) — 0; 0; 1 units on a scale
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Association of Baseline FMISO PET and MRI Features With OS as Assessed Using Cox-regression Model — 25; 22; 24; 20 Participants — p=0.048
Brain and Central Nervous System Tumors
Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63
Brain and Central Nervous System Tumors
Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…